Compare Organon & Co. Common Stock (OGN) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Energy Select Sector SPDR Fund — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Energy Select Sector SPDR Fund trades at $68.08 (market cap $42.98B). The key difference: Energy Select Sector SPDR Fund is far larger — about 11.9× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Energy Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Energy Select Sector SPDR Fund for 68 Days on average.
| OGN | XLE | |
|---|---|---|
Market Cap | $3.62B | $42.98B |
Volume | 2,892,999 | 27,490,546 |
Sector | Health | — |
52-Week High | $13.81 | $67.61 |
52-Week Low | $5.70 | $42.64 |
Typical Hold Time | 0 Days | 68 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
XLE trades at $67.17, up 1.74% on the day, with a bullish technical signal driven by moving averages and strong momentum indicators. The ETF's performance is closely tied to oil price dynamics, with recent news highlighting supply disruptions and geopolitical tensions supporting energy sector strength. Key support lies near $65, while resistance is seen around $67.
Outlook remains positive near-term due to oil market tightness, but risks include potential price reversals and sector volatility. Investors should weigh the ETF's concentrated oil and gas exposure against broader energy infrastructure alternatives for diversified income and stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
